Table 2.
Anti-RBD IgG levels at 8 weeks post initial vaccine dose
| Ocrelizumab | Natalizumab | Fumarate | Interferon beta | p value | |
|---|---|---|---|---|---|
| 8-Week analysis | |||||
| n | 16 | 12 | 11 | 6 | |
| Anti-RBD GMT ± geometric SD | 1.1 ± 0.7 | 210.3 ± 1.9 | 248.4 ± 1.8 | 184.0 ± 2.6 | < 0.0001 |
| Any detectable anti-RBD IgG, n (%) | 4 (25) | 12 (100) | 11 (100) | 6 (100) | < 0.0001 |
| > Twofold increase, n (%) | 4 (25) | 12 (100) | 11 (100) | 6 (100) | < 0.0001 |
| > Fourfold increase, n (%) | 1 (6.3) | 12 (100) | 11 (100) | 6 (100) | < 0.0001 |
| 24-Week analysis | |||||
| n | 4 | 10 | 9 | 6 | |
| Anti-RBD GMT ± geometric SD | 0.5 ± 1.0 | 44.8 ± 2.1 | 46.2 ± 1.5 | 27.8 ± 2.7 | 0.012 |
| > Twofold increase, n (%) | 0 (0) | 10 (100) | 9 (100) | 6 (100) | < 0.0001 |
| > Fourfold increase, n (%) | 0 (0) | 10 (100) | 9 (100) | 6 (100) | < 0.0001 |
| 36-Week analysis | |||||
| n | 8a | 7 | 8 | 4 | |
| Anti-RBD GMT ± geometric SD | 0.5 ± 1.0 | 23.7 ± 2.8 | 16.7 ± 1.8 | 10.0 ± 2.7 | 0.008 |
| > Twofold increase, n (%) | 0 (0) | 7 (100) | 8 (100) | 4 (100) | < 0.0001 |
| > Fourfold increase, n (%) | 0 (0) | 7 (100) | 8 (100) | 4 (100) | < 0.0001 |
GMT values were compared using one-way analysis of variance with Tukey’s correction for multiple comparisons
Anti-RBD IgG SARS-CoV-2 spike receptor binding domain, GMT geometric mean titer
aTwo participants in the ocrelizumab cohort received prophylactic tixagevimab/cilgavimab to prevent COVID-19 infections and were therefore excluded from 36-week anti-RBD GMT analyses because of cross-reactivity